Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2008

View Archived Issues

Inspire initiates second phase III denufosol tetrasodium trial in cystic fibrosis

Cellegy enters definitive merger agreement with Adamis

Dara BioSciences and Point Therapeutics consummate merger

Altor signs agreement with Genentech for antibody-based tissue factor antagonists

Serotonin system involved in chronic L-DOPA wearing-off effect

Recent Amgen patent discloses new treatment for idiopathic pulmonary fibrosis

Results from Merck & Co. HIV vaccine reported at the CROI meeting

Sublingual route effective for influenza vaccine in mice

Robust immune responses with multiclade HIV-1 DNA plasmid vaccine in phase I/II studies

EMEA accepts for filing sanofi pasteur's MAA for seasonal influenza vaccine

Mesoblast reports positive results from clinical trial of adult stem cells in fracture healing

FDA issues special protocol assessment to Wilex for phase III trial of CA9-SCAN

Raven completes enrollment in phase I/IIa clinical trial of RAV-12 therapeutic antibody

Lipoxen and the Serum Institute of India initiate dosing in phase I trial of ErepoXen

Novel anti-HIV agents described in recent Merck patent

New therapeutic agents for HCV infection reported in recent patent literature

Bioniche presents update on Urocidin trial in refractory bladder cancer

FDA grants fast track status to Boehringer Ingelheim's BIBW-2992 for NSCLC

Qiagen and Center for Molecular Medicine research molecular diagnostic markers

YM Biosciences enrolls first patient in phase II nimotuzumab trial in brain cancer

Dainippon Sumitomo recaps Q3 developments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...